Trial in progress: A Phase IIb randomized clinical trial combining oral azacitidine and vididencel, a novel immunotherapy, for post-remission / maintenance therapy for adult patients with cytogenetically intermediate and high-risk Acute Myeloid Leukemia (ALLG AMLM22/D4 CADENCE)

Victoria Ling; Paula Marlton; John Reynolds; Mark Dawson; Robin Gasiorowski; Hannah Rose; Chun Yew Fong; Jake Shortt; Anoop Enjeti; Carolyn Grove; Joanna Nkyekyer; Nadia Munsef; Andrew Wei

doi:10.1182/blood-2025-5210

Trial in progress: A Phase IIb randomized clinical trial combining oral azacitidine and vididencel, a novel immunotherapy, for post-remission / maintenance therapy for adult patients with cytogenetically intermediate and high-risk Acute Myeloid Leukemia (ALLG AMLM22/D4 CADENCE)

Victoria Ling, Paula Marlton, John Reynolds, Mark Dawson, Robin Gasiorowski, Hannah Rose, Chun Yew Fong, Jake Shortt, Anoop Enjeti, Carolyn Grove, Joanna Nkyekyer, Nadia Munsef, Andrew Wei

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Pages (from-to)	5210-5211
Number of pages	2
Journal	Blood
Volume	146
Issue number	Supplement 1
Early online date	2025
DOIs	https://doi.org/10.1182/blood-2025-5210
Publication status	Published - 3 Nov 2025
Externally published	Yes
Event	67th Annual Meeting of the American-Society-of-Hematology (ASH) - Orlando Duration: 6 Dec 2025 → 9 Dec 2025

Access to Document

10.1182/blood-2025-5210

Cite this

Ling, V., Marlton, P., Reynolds, J., Dawson, M., Gasiorowski, R., Rose, H., Fong, C. Y., Shortt, J., Enjeti, A., Grove, C., Nkyekyer, J., Munsef, N., & Wei, A. (2025). Trial in progress: A Phase IIb randomized clinical trial combining oral azacitidine and vididencel, a novel immunotherapy, for post-remission / maintenance therapy for adult patients with cytogenetically intermediate and high-risk Acute Myeloid Leukemia (ALLG AMLM22/D4 CADENCE). Blood, 146(Supplement 1), 5210-5211. https://doi.org/10.1182/blood-2025-5210

Ling, Victoria ; Marlton, Paula ; Reynolds, John et al. / Trial in progress : A Phase IIb randomized clinical trial combining oral azacitidine and vididencel, a novel immunotherapy, for post-remission / maintenance therapy for adult patients with cytogenetically intermediate and high-risk Acute Myeloid Leukemia (ALLG AMLM22/D4 CADENCE). In: Blood. 2025 ; Vol. 146, No. Supplement 1. pp. 5210-5211.

@article{e788169d6500430cae15ff594ce5611e,

title = "Trial in progress: A Phase IIb randomized clinical trial combining oral azacitidine and vididencel, a novel immunotherapy, for post-remission / maintenance therapy for adult patients with cytogenetically intermediate and high-risk Acute Myeloid Leukemia (ALLG AMLM22/D4 CADENCE)",

author = "Victoria Ling and Paula Marlton and John Reynolds and Mark Dawson and Robin Gasiorowski and Hannah Rose and Fong, \{Chun Yew\} and Jake Shortt and Anoop Enjeti and Carolyn Grove and Joanna Nkyekyer and Nadia Munsef and Andrew Wei",

year = "2025",

month = nov,

day = "3",

doi = "10.1182/blood-2025-5210",

language = "English",

volume = "146",

pages = "5210--5211",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier",

number = "Supplement 1",

note = "67th Annual Meeting of the American-Society-of-Hematology (ASH) ; Conference date: 06-12-2025 Through 09-12-2025",

}

Ling, V, Marlton, P, Reynolds, J, Dawson, M, Gasiorowski, R, Rose, H, Fong, CY, Shortt, J, Enjeti, A, Grove, C, Nkyekyer, J, Munsef, N & Wei, A 2025, 'Trial in progress: A Phase IIb randomized clinical trial combining oral azacitidine and vididencel, a novel immunotherapy, for post-remission / maintenance therapy for adult patients with cytogenetically intermediate and high-risk Acute Myeloid Leukemia (ALLG AMLM22/D4 CADENCE)', Blood, vol. 146, no. Supplement 1, pp. 5210-5211. https://doi.org/10.1182/blood-2025-5210

Trial in progress: A Phase IIb randomized clinical trial combining oral azacitidine and vididencel, a novel immunotherapy, for post-remission / maintenance therapy for adult patients with cytogenetically intermediate and high-risk Acute Myeloid Leukemia (ALLG AMLM22/D4 CADENCE). / Ling, Victoria; Marlton, Paula; Reynolds, John et al.
In: Blood, Vol. 146, No. Supplement 1, 03.11.2025, p. 5210-5211.

Research output: Contribution to journal › Meeting abstract › peer-review

TY - JOUR

T1 - Trial in progress

T2 - 67th Annual Meeting of the American-Society-of-Hematology (ASH)

AU - Ling, Victoria

AU - Marlton, Paula

AU - Reynolds, John

AU - Dawson, Mark

AU - Gasiorowski, Robin

AU - Rose, Hannah

AU - Fong, Chun Yew

AU - Shortt, Jake

AU - Enjeti, Anoop

AU - Grove, Carolyn

AU - Nkyekyer, Joanna

AU - Munsef, Nadia

AU - Wei, Andrew

PY - 2025/11/3

Y1 - 2025/11/3

U2 - 10.1182/blood-2025-5210

DO - 10.1182/blood-2025-5210

M3 - Meeting abstract

SN - 0006-4971

VL - 146

SP - 5210

EP - 5211

JO - Blood

JF - Blood

IS - Supplement 1

Y2 - 6 December 2025 through 9 December 2025

ER -

Ling V, Marlton P, Reynolds J, Dawson M, Gasiorowski R, Rose H et al. Trial in progress: A Phase IIb randomized clinical trial combining oral azacitidine and vididencel, a novel immunotherapy, for post-remission / maintenance therapy for adult patients with cytogenetically intermediate and high-risk Acute Myeloid Leukemia (ALLG AMLM22/D4 CADENCE). Blood. 2025 Nov 3;146(Supplement 1):5210-5211. Epub 2025. doi: 10.1182/blood-2025-5210